Preliminary Report on Impact of Immulite 2000 Cortisol antibody change October 2020 including evaluation of manufacturer recommended adjustment factors

Peter Graham, University of Nottingham, ESVE EQA Co-ordinator

Updated 3rd November 2020 (First report 23rd October, Second Report 27th Oct, Third Report 29th October)

Based on 466 results from 10 labs submitted through an online shared spreadsheet.

The most up-to-date version of this document is <u>here</u>.


Raw results from Lot 550 and beyond

See next section for evaluation of manufacturer recommended adjustment factors

Serum Overall (canine)

Overall there is negative bias in the results following the antibody change (-23%). The bias varies across concentrations which may make the implementation of simple equipment correction factors difficult as a means to address the change.

| N = | 401 | | | |
|---------------------------------------|----------------|--------------------------------|---------------------|-------------------|
| | Minimum | Maximum | | |
| Before 550 | 27 | 1380 | | |
| 550 and after | 27 | 1311 | | |
| Average Bias nmol/L Average Bias % | -40 -22.8 | | | |
| | | | | |
| Cortisol range nmol/l | n | Average %Bias | % Bias rai | nge |
| Cortisol range nmol/l <50 | n 77 | - | % Bias rai -46.7 | 1ge 3.0 |
| • | | %Bias | | • |
| <50 | 77 | %Bias -15.1 | -46.7 | 3.0 |
| <50 50-150 | 77 152 | %Bias -15.1 -26.9 | -46.7 -134.5 | 3.0 3.9 |



If adjustment of cut-off values is a consideration, the following are the outcome of simple linear regression.

| Original Cut- off | Regression derived adjusted cut-off |
|----------------------|--|
| 40 | 29 |
| 50 | 37 |
| 138 | 110 |

| 150 | 120 |
|-----|-----|
| 250 | 203 |
| 500 | 410 |
| 550 | 452 |
| 600 | 493 |

Subjective visual assessment of paired results may also help in deciding new interpretative guidance:


| For 40nmo | ol/I: | For 50 nm | ol/L: | For | 138 nn | nol/I: |
|------------------------|--------|-------------|--------|------|---------|--------|
| Previous | New | Previous | New | Pre | evious | New |
| 38 | 29.8 | 48 | 30.3 | | 135 | 106 |
| 38 | 27.6 | 48 | 36 | | 136 | 131 |
| 38 | 30 | 49 | 50.5 | : | 136 | 75 |
| 38.6 | 32.8 | 49.1 | 34.2 | : | 138 | 27.6 |
| 38.6 | 28.1 | 49.7 | 42.8 | | 139 | 104 |
| 39 | 30 | 51 | 41.9 | | 141 | 115 |
| 39.5 | 27.9 | 51 | 41.5 | | 141 | 128 |
| 39.5 | 29.8 | 51 | 46 | | 41.6 | 131.1 |
| 40 | 29.5 | 52 | 37.5 | | 142 | 119 |
| 41 | 33 | | | | 142 | 113 |
| 41 | 29 | 52.1 | 28.4 | | 142 | 123 |
| 41 | 35 | e.g., 40nm | nol/L | | 142 | 105 |
| 41.9 | 27.6 | | | e.a. | , 110 r | mol/l |
| 42 | 33 | | | c.g. | , 110 . | |
| 42 | 32 | | | | | |
| e.g. 30nm For 150nm | | For 250 nn | nol/L: | For | 500 nn | nol/l |
| Previous | New | Previous | New | Pre | evious | New |
| 145 | 140 | 241 | 204 | | 172 | 441 |
| 147 | 103 | 244 | 244 | | 483 | 414 |
| 149 | 127 | 246 | 223 | | | |
| 149 | 139 | 248.7 | 266.6 | | 488 | 417 |
| 150 | 113 | 255 | 224 | | 194 | 403 |
| 151 | 110 | 260 | 183 | | 199 | 505 |
| 152 | 107 | o a 200 r | mol/l | Ę | 508 | 425 |
| 153 | 98.2 | e.g., 200 r | | Ę | 516 | 367 |
| 154 | 109 | | | 5 | 527 | 411 |
| 155 | 99 | | | Ę | 530 | 395 |
| e.g., 120n | mol/L | | | e.g. | , 400n | mol/l |
| For 550 nn | nol/L: | For 600 nn | no/I: | | | |
| Previous | New | Previous | New | | | |

| 538 | 477 | 574 | 328 | |
|------------|--------|-----------|--------|--|
| 538 | 384 | 577 | 491 | |
| 538 | 552 | 579 | 502 | |
| 549 | 323 | 582 | 494 | |
| 574 | 328 | 588 | 461 | |
| 577 | 491 | 588 | 568 | |
| 450 | | 588 | 519 | |
| e.g. 450 r | nmol/L | 635 | 430 | |
| | | e.g., 500 | nmol/L | |

Trilostane samples (within 12hrs of dose, canine)

On earlier versions of this evaluation, it appeared that the "within 12 hours of Trilostane" subset was less dramatically affected. However, with more data-points, it appears that this subset has similar bias to the "all canine sera" data. A separate analysis was performed because manufacturer information includes a change in antibody cross reactivity with adrenal steroid pre-cursors. Trilostane has been reported to cause an accumulation of adrenal steroid precursors.

| N = | 32 | | | |
|---------------------------------------|--------------|------------------|----------------|------|
| | Minimum | Maximum | | |
| Before 550 | 27 | 384 | | |
| 550 and after | 27 | 348 | | |
| Average Bias nmol/L Average Bias % | -19 -20.2 | | | |
| Cortisol range nmol/l | n | Average %Bias | % Bias rang | ge |
| <50 | 10 | -6.4 | -27.5 | 1.2 |
| 50-150 | 11 | -37.7 | -134.5 | 1.0 |
| 150 250 | - | 45.0 | 40 - | 447 |
| 150-250 | 9 | -15.9 | -40.7 | 14.7 |
| 250-500 | 9 2 | -15.9 -11.9 | -40.7 -14.0 | -9.8 |




This data subset included trilostane monitoring ACTH stimulations tests (usually with 6 hours of trilostane dose). It did not include "pre-Vetoryl-cortisol" which is usually sampled at 12 or 24hrs after administration.

Urine

The ESVE collaboration data is "urine cortisol" rather than "urine corticoid:creatinine ratio".

Presumably as a result of the new antibody having different cross-reactivity profile for urinary corticoid metabolites, the bias impact on urine cortisol (around -70%) seems to be much greater than that on serum.

| N= | 44 | | | |
|-----------------------------|---------|------------------|--------------|----|
| | Minimum | Maximum | | |
| Before 550 | 59.3 | 1380 | | |
| 550 and after | 43.6 | 695 | | |
| | | | | |
| Average Bias nmol/L | -198 | | | |
| Average Bias % | -72.5 | | | |
| Urine Cortisol range nmol/l | n | Average %Bias | % Bias range | |
| 100-200 | 7 | -75.2 | -96.6 -34. | 6 |
| 200-500 | 25 | -75.1 | -122.3 -21. | .1 |
| >500 | 11 | -68.5 | -96.0 -37. | 4 |



A substantial decrease in cut-off values for UCCR will be required (e.g. to possibly 10 from 30). The coloration does not have creatinine values in the data-file to be able to confirm new suggested cut-offs, but on average it would be around 30% of original.

Other species

Only a very small number of paired results are so far available for horse (n=6) and cats (n=3). So far, the data suggest that the impact on cats may be similar to dogs but that for horses it may be less.

| Species | Before Lot 550 | After Lot 550 | Average | Bias (nmol/l) | Bias % |
|---------|-------------------|------------------|---------|------------------|--------|
| Species | 201 330 | | • | · , | |
| Feline | 74 | 56 | 65 | -18 | -27.7 |
| Feline | 98 | 69 | 83.5 | -29 | -34.7 |
| Feline | 32 | 27.6 | 29.5 | -5 | -16.9 |
| Equine | 126 | 111 | 118.5 | -15 | -12.7 |
| Equine | 51 | 38 | 44.5 | -13 | -29.2 |
| Equine | 154 | 173 | 163.5 | 19 | 11.6 |
| Equine | 187 | 171 | 179 | -16 | -8.9 |
| Equine | 160 | 152 | 156 | -8 | -5.1 |
| Equine | 113 | 108 | 110.5 | -5 | -4.5 |

Results incorporating manufacturer adjustment factors in Lot 550 and

beyond

Siemens has proposed the following adjust formula to mitigate the impact of the antibody change. Initially labs would need to be incorporate it LIMS systems but eventually to be included in veterinary specific reagent barcodes and reagent packs.

historical value = (1.1 x new antibody kit value) + 4.14 nmol/L


The ESVE collaboration data has been reanalysed to assess the impact of the manufacturer correction factor.


The correction factor shifts the reportable range from 27.6 to 1380 to 34.5 to 1446

Serum Overall (canine)

Overall there is negative bias in the results following the antibody change (-23%). The bias varies across concentrations which may make the implementation of simple equipment correction factors difficult as a means to address the change.

| N= | 401 | | | |
|---------------------------------------|-------------|------------------|-----------------|--------------|
| | Minimum | Maximum | | |
| Before 550 | <27.6 | 1380 | | |
| Adj 550 and after | <34.5 | 1446 | | |
| Average Bias nmol/L Average Bias % | -19 -8.2 | | | |
| Cortisol range nmol/l | n | Average %Bias | % Bias ra | nge |
| -50 | | | | |
| <50 | 77 | 6.8 | -25.1 | 22.2 |
| <50 50-150 | 77 152 | 6.8 -12.1 | -25.1 -121.2 | 22.2 16.9 |
| | | | | |
| 50-150 | 152 | -12.1 | -121.2 | 16.9 |





If adjustment of cut-off values is a consideration, the following are the outcome of simple linear regression.

| Original Cut- off | Regression derived adjusted cut-off |
|----------------------|--|
| 40 | 36 |
| 50 | 45 |
| 138 | 126 |
| 150 | 136 |
| 250 | 228 |
| 500 | 456 |
| 550 | 501 |
| 600 | 547 |

Subjective visual assessment of paired results may also help in deciding new if a change in interpretative guidance is necessary:


| For 40r | nmol/I: | | For 50 nm | ol/L: | For 138 n | mol/I: |
|---------|-----------|---|-------------|--------------|-----------|--------|
| Previo | us New |] | Previous | New | Previous | New |
| 38 | 36.9 | | 48 | 37.5 | 135 | 120.7 |
| 38 | 34.5 | | 48 | 43.7 | 136 | 148.2 |
| 38 | 37.1 | | 49 | 59.7 | 136 | 86.6 |
| 38.6 | 40.2 | | 49.1 | 41.8 | 138 | 34.5 |
| 38.6 | 35.1 | | 49.1 | 41.0 51.2 | 139 | 118.5 |
| 39 | 37.1 | | 51 | | 141 | 130.6 |
| 39.5 | 34.8 | | 51 | 50.2 | 141 | 144.9 |
| 39.5 | 36.9 | | 51 | 56.6 54.7 | 141.6 | 148.4 |
| 40 | 36.6 | | 52 | | 142 | 135.0 |
| 41 | 40.4 | | | 45.4 | 142 | 128.4 |
| | | | 52.1 | 35.4 | 142 | 139.4 |
| 41 | 36.0 | | o g 22 po | change | 142 | 119.6 |
| 41 | 42.6 | | e.g., ?? no | change | 105 | |
| 41.9 | | | | | e.g., 125 | nmol/l |
| 42 | 40.4 | | | | | |
| 42 | 39.3 | | | | | |
| e.g. ?? | No change | | | | | |

| For 150nm | nol/I: | For 250 nr | nol/L: | | For 500 nmol/l | | |
|--------------------------|--------|--------------|--------|---|----------------|-------|--|
| Previous | New | Previous | New | | Previous | New | |
| 145 | 158.1 | 241 | 228.5 | | 472 | 489.2 | |
| 147 | 117.4 | 244 | 272.5 | | 483 | 459.5 | |
| 149 | 143.8 | 246 | 249.4 | | 488 | 462.8 | |
| 149 | 157.0 | 248.7 | 297.4 | | 494 | 402.0 | |
| 150 | 128.4 | 255 | 250.5 | | | | |
| 151 | 125.1 | 260 | 205.4 | | 499 | 559.6 | |
| 152 | 121.8 | e.g., ?? no | change | | 508 | 471.6 | |
| 153 | 112.2 | e.g., :: 110 | change | | 516 | 407.8 | |
| 154 | 124.0 | | | | 527 | 456.2 | |
| 155 | 113.0 | | | | 530 | 438.6 | |
| e.g., 135n For 550 nr | - | For 600 nr | no/I: | , | e.g., 450n | mol/l | |
| Previous | New | Previous | New | | | | |
| 538 | 528.8 | 574 | 364.9 | | | | |
| 538 | 426.5 | 577 | 544.2 | | | | |
| 538 | 611.3 | 579 | 556.3 | | | | |
| 549 | 359.4 | 582 | 547.5 | | | | |
| 574 | 364.9 | 588 | 511.2 | | | | |
| 577 | 544.2 | 588 | 628.9 | | | | |
| | | 588 | 575.0 | | | | |
| e.g. 500 n | mol/L | 635 | 477.1 | | | | |
| | | e.g., 550 r | nmol/L | | | | |

Trilostane samples (within 12hrs of dose, canine)

A separate analysis was performed because manufacturer information includes a change in antibody cross reactivity with adrenal steroid pre-cursors. Trilostane has been reported to cause an accumulation of adrenal steroid precursors.

| N = | 32 | | | |
|-----------------------|---------|---------|--------------|------|
| | Minimum | Maximum | | |
| Before 550 | 27.6 | 384 | | |
| Adj 550 and after | 34.5 | 387 | | |
| | | | | |
| Average Bias nmol/L | -5 | | | |
| Average Bias % | -4.1 | | | |
| | | | | |
| _ | | Average | | |
| Cortisol range nmol/l | n | %Bias | % Bias range | |
| <50 | 10 | 15.9 | -3.1 | 22.2 |
| 50-150 | 11 | -22.9 | -120.0 | 15.1 |
| 150-250 | 9 | -3.9 | -28.2 | 25.8 |
| | | | | |
| 250-500 | 2 | -1.2 | -3.1 | 0.8 |




This data subset included trilostane monitoring ACTH stimulations tests (usually with 6 hours of trilostane dose). It did not include "pre-Vetoryl-cortisol" which is usually sampled at 12 or 24hrs after administration.

Urine

The ESVE collaboration data is "urine cortisol" rather than "urine corticoid:creatinine ratio".

Presumably as a result of the new antibody having different cross-reactivity profile for urinary corticoid metabolites, the bias impact on urine cortisol seems to be much greater than that on serum. The correction formula derived for serum does not correct urine results and so new interpretative guidance

| n | 44 | | | | |
|-----------------------|---------|---------|---------------|---------------|--|
| | Minimum | Maximum | | | |
| Before 550 | 59.3 | 1380 | | | |
| Adj 550 and after | 52.1 | 769 | | | |
| | | | | | |
| Average Bias nmol/L | -175 | | | | |
| Average Bias % | -61.4 | | | | |
| | | | | | |
| | | Average | | | |
| Cortisol range nmol/l | n | %Bias | % Bias ranges | % Bias ranges | |
| 100-200 | 7 | -61.7 | -82.7 -2 | 22.5 | |
| 200-500 | 25 | -64.2 | -112.4 - | 9.9 | |
| >500 | 11 | -59.1 | -86.9 -2 | 27.2 | |



A substantial decrease in cut-off values for UCCR will be required The coloration does not have creatinine values in the data-file to be able to confirm new suggested cut-offs, but on average it would be around 40% of original.

Other species

Only a very small number of paired results are so far available for horse (n=6) and cats (n=3). So far, the data suggest that the impact on cats may be similar to dogs but that for horses there may be a positive bias. More data are required.

| | Before | Adj After | | Bias | |
|---------|---------|-----------|---------|----------|--------|
| Species | Lot 550 | Lot 550 | Average | (nmol/l) | Bias % |
| Feline | 74 | 66 | 69.9 | -8.3 | -11.8 |
| Feline | 98 | 80 | 89.0 | -18.0 | -20.2 |
| Feline | 32 | <33.8 | 32.9 | 1.8 | 5.6 |
| Equine | 126 | 126 | 126.1 | 0.2 | 0.2 |
| Equine | 51 | 46 | 48.5 | -5.1 | -10.4 |
| Equine | 154 | 194 | 174.2 | 40.4 | 23.2 |
| Equine | 187 | 192 | 189.6 | 5.2 | 2.8 |
| Equine | 160 | 171 | 165.7 | 11.3 | 6.8 |
| Equine | 113 | 123 | 118.0 | 9.9 | 8.4 |